Skip to content
Trial Agents

Veeda Clinical Research

Veeda Clinical Research is recorded as a service provider in 45 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.

45distinct trials
20recorded service labels
1trials with learnings

Data snapshot: 2026-10-09 · About the data

Clinical trial experience

Showing 20 of 45 trials · Latest update first

A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).

Sponsor Eikon Therapeutics Inc.

Start (EU)
Latest update
Estimated end

EPIK-P2: A Phase II double-blind study with an upfront, 16-week randomized, placebo-controlled period, to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)

Sponsor Novartis Pharma AG

Start (EU)
Latest update
Estimated end

A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by blinatumomab in pediatric, adolescent, and young adult patients with relapsed or refractory BCR::ABL1-positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

Sponsor Novartis Pharma AG

Start (EU)
Not reported
Latest update
Estimated end

A multi-center, open-label study to determine the dose and safety of oral asciminib in pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitors.

Sponsor Novartis Pharma AG

Start (EU)
Latest update
Estimated end

A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies

Sponsor Novartis Pharma AG

Start (EU)
Latest update
Estimated end

A Phase 2, open-label study to evaluate the efficacy and safety of rapcabtagene autoleucel in patients with active, refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN).

Sponsor Novartis Pharma AG

Start (EU)
Latest update
Estimated end

A multi-center, randomized, double-blind, placebo-controlled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients

Sponsor Novartis Pharma AG

Start (EU)
Latest update
Estimated end
Operational learnings available3 trial-level findings · Read insights
  • A March 2023 amendment increased planned enrollment from 450 to 470 participants and expanded the SRI population from approximately 20 to 40 participants to enable more comprehensive PK characterization.
  • A March 2021 amendment required IgA nephropathy background medication in addition to ACE inhibitor/ARB therapy to be stable for at least 90 days before first dose and throughout the study, and changed the pharmacological steroid threshold from more than 10 mg/day to more than 7.5 mg/day prednisone/prednisolone equivalent.
  • Change from baseline in eGFR at 9 months was promoted from exploratory to secondary and added to the interim testing strategy in April 2022, then removed from the testing strategy in March 2023 following FDA alignment.

These findings describe the trial, not the service provider’s performance or responsibility.

TulmiSTAR-01: A two-part, Phase I dose escalation and expansion followed by a randomized, open-label multicenter, Phase II study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard of care in patients with progressive metastatic castrate resistant prostate cancer

Sponsor Novartis Pharma AG

Start (EU)
Latest update
Estimated end

A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of LTP001 in healthy adult participants (Part A) and to evaluate the efficacy and safety of LTP001 for the treatment of participants with pulmonary arterial hypertension (Part B)

Sponsor Novartis Pharma AG

Start (EU)
Latest update
Estimated end

A phase Ib/II open-label, multi-center study of the DNA protein kinase inhibitor AMO959 with lutetium (177Lu) vipivotide tetraxetan (AAA617) in combination with an androgen receptor pathway inhibitor (ARPI) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC)

Sponsor Novartis Pharma AG

Start (EU)
Latest update
Estimated end

Questions about this trial experience

What services are recorded for Veeda Clinical Research?

The 2026-10-09 snapshot links Veeda Clinical Research to 45 distinct CTIS trials. Recorded services include Laboratory services, Pharmacokinetic sample analysis, PK analysis, Central Pharmacokinetic (PK) bioanalysis, among 20 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.

Which therapeutic areas and study phases are recorded for Veeda Clinical Research?

The most frequently recorded therapeutic areas are Solid Tumor Oncology, Immunology, Nephrology, Haematological Malignancies. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.

In which countries are trials linked to Veeda Clinical Research conducted?

The linked trials record locations in 22 countries, including Germany, France, Spain, Italy, Netherlands. These are trial locations, not confirmed office locations or countries where Veeda Clinical Research delivered services.

What can this page tell me about Veeda Clinical Research's trial experience?

Browse 45 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.

About this data & company names

One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.

Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.

Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Veeda Clinical Research. Legacy brands remain separate unless explicitly matched in the name registry.

View recorded company names
  • Veeda Clinical Research Limited

Never miss a new clinical trial insight

We continuously analyze new and updated clinical trial data and publish practical, evidence-led reports for clinical leaders.

By entering your email, you agree to receive emails from Trial Agents. You can unsubscribe anytime.